Premium
Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo
Author(s) -
Cook Robert L.,
Zhou Zhi,
Miguez Maria Jose,
Quiros Clery,
Espinoza Luis,
Lewis John E.,
Brumback Babette,
Bryant Kendall
Publication year - 2019
Publication title -
alcoholism: clinical and experimental research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 153
eISSN - 1530-0277
pISSN - 0145-6008
DOI - 10.1111/acer.14130
Subject(s) - medicine , placebo , naltrexone , randomized controlled trial , young adult , receptor , alternative medicine , pathology , opioid
Background Alcohol consumption is associated with poor health outcomes in women living with HIV (WLWH), but whether medication can help to reduce drinking in non–treatment‐seeking women or whether reduction in drinking improves HIV outcomes is unclear. We conducted a randomized clinical trial (RCT) of daily oral naltrexone (50 mg) versus placebo in WLWH who met criteria for current unhealthy alcohol use. Methods WLWH with current unhealthy alcohol use (>7 drinks/wk or >3 drinks/occasion) were randomly assigned to daily oral naltrexone 50 mg ( n = 96) or placebo ( n = 98) for 4 months. Drinking outcomes, including the proportion of women who reduced (